PD-L1 testing and detection of EGFR mutations, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, and RET should be performed in patients with adenocarcinoma, large cell lung cancer and NSCLC not otherwise specified (NOS). This evidence concerns the gene CD274 and adenocarcinoma.